NORTHBROOK, Ill – September 19, 2012 — Clarus Therapeutics, Inc., today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,241,664 entitled, “Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same.” The U.S. patent relates to the formulation of testosterone prodrugs for oral administration with enhanced absorption and bioavailability. Specifically, the patent covers Clarus’ oral testosterone product, CLR-610, which is in Phase 3 development for the clinical management of low testosterone in men. It is expected that the patent will provide Clarus with U.S. patent protection at least through April 2028. Additional patent applications are pending in the U.S. and other key countries.

Robert E. Dudley, Ph.D., president and chief executive officer of Clarus Therapeutics states, “The protection offered by this patent not only covers CLR-610, but in addition, protects other testosterone ester formulations and their use in the treatment of testosterone deficiency. With our newly issued patent, we have enhanced our ability to protect our proprietary technology from potential competitors – an important consideration especially as we advance CLR-610 through its last stages of clinical development.”

About Clarus Therapeutics
Clarus is a privately held biopharmaceutical company focused on the development and commercialization of our oral T replacement product, currently undergoing Phase 3 clinical testing. According to the American Urological Association, 10% of men 40-to-60 years of age, and 20% over the age of 60 have low T levels. Common symptoms associated with low T may include mild depression, reduced sex drive and erectile function, increased body fat, and decreased energy, lean body mass, muscle strength and bone mineral density. For more information, please visit:

# # #